

References

S-145

1. S. National Institutes of Health. ClinicalTrials.gov. Randomized EsophyX versus sham/placebo Controlled TIF trial: The RESPECT study. ClinicalTrials.gov Identifier: NCT01136980.
2. S. National Institutes of Health. ClinicalTrials.gov. The EndoGastric solutions TEMPO trial. ClinicalTrials.gov Identifier: NCT01647958.
3. Trad KS, Barnes WE, Prevou ER, et al. The TEMP trial at 5 years: Transoral funduplications (TIF 2.0) is safe, durable and cost-effective. *Surg Innov.*
4. Testoni PA, Testoni S, Distefano G, et al. Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: Clinical efficacy is maintained up to 10 years. *Endosc Int Open.* 2019;7(05):E647-54.
5. De Moura EG, Sallum RA, Nasi A, et al. Endoscopic polymer injection and endoluminal plication in treatment of gastroesophageal reflux disease: Evaluation of long-term results. *Endosc Int Open.* 2018;6(05):E630-6.
6. McCarty TR, Itidiare M, Njei B, Rustagi T. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: A systematic review and meta-analysis. *Endoscopy.* 2018;50(7):708-725.
7. Trad KS, Barnes WE, Prevou ER, et al. The TEMPO trial at 5 years: Transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. *Surg Innov.* 2018;25(2):149-157.
8. Ma L, Li T, Liu G, et al. Stretta radiofrequency treatment vs toupet fundoplication for gastroesophageal reflux disease: A comparative study. *BMC Gastroenterol.* 2020;20(1):162.
9. Ihde GM. The evolution of TIF: Transoral incisionless fundoplication. *Therap Adv Gastroenterol.* 2020;13:1-17.
10. Testoni S, Hassan C, Mazzoleni G, et al. Long-term outcomes of transoral incisionless fundoplication for gastro-esophageal reflux disease: Systematic-review and meta-analysis. *Endosc Int Open.* 2021;9(2):E239-E246.

11. Bell RCW, Freeman K, Heidrick R, Ayazi S. Transoral incisionless fundoplication demonstrates durability at up to 9 years. *Therap Adv Gastroenterol.* 2021;14:1-11.
12. Xie P, Yan J, Ye L, et al. Efficacy of different endoscopic treatments in patients with gastroesophageal reflux disease: A systematic review and network meta-analysis. *Surg Endosc.* 2021;35(4):1500-1510.
13. Dekonenko C, Holcomb GW 3rd. Laparoscopic fundoplication for the surgical management of gastroesophageal reflux disease in children. *Eur J Pediatr Surg.* 2020;30(2):150-155.
14. Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. *Gut Liver.* 2018;12(1):7-16.
15. McKinley SK, Dirks RC, Walsh D, et al. Surgical treatment of GERD: Systematic review and meta-analysis. *Surg Endosc.* 2021;35(8):4095-4123.
16. Slater BJ, Dirks RC, McKinley SK, et al. SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD). *Surg Endosc.* 2021;35(9):4903-4917.
17. Antiporda M, Jackson C, Smith CD, Thomas M, Elli EF, Bowers SP. Strategies for surgical remediation of the multi-fundoplication failure patient. *Surg Endosc.* 2019;33(5):1474-1481.
18. Testoni S, Hassan C, Mazzoleni G, et al. Long-term outcomes of transoral incisionless fundoplication for gastro-esophageal reflux disease: Systematic-review and meta-analysis. *Endosc Int Open.* 2021;9(2):E239-E246.
19. Testoni SGG, Cilona MB, Mazzoleni G, et al. Transoral incisionless fundoplication with Medigus ultrasonic surgical endostapler (MUSE) for the treatment of gastro-esophageal reflux disease: outcomes up to 3 years. *Surg Endosc.* 2022;36(7):5023-5031.
20. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol.* 2022;117(1):27-56.
21. Society of American Gastrointestinal and Endoscopic Surgeons. Multi-Society Consensus Conference and Guideline on the Treatment of Gastroesophageal Reflux Disease (GERD). July 2022.